Lupus & antiphospholipid syndrome
A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The Hydroxychloroquine (HCQ) ‐ SAFE Study
Authors' conclusion
HCQ-SAFE is a feasible SDM intervention with the potential to improve adherence and reduce decisional conflicts.
Study context
- Population
- Adults with systemic lupus erythematosus (SLE) on HCQ, eight clinics in two health systems90% female
- Participants
- 200 adults
- Comparison
- Post-HCQ-SAFE intervention vs baseline
- Outcome
- Mean change in HCQ adherence (proportion of days covered) and Decisional Conflict Scale scores post-intervention vs baseline
Methodological detailspre–post (intervention vs baseline), multicentre (eight clinics in two health systems), paired t-test and adjusted linear regression, HCQ-SAFE developed in English and Spanish using an iterative process with 30 patient and clinician advisers
- Pre–post (intervention vs baseline)
- Multicentre (eight clinics in two health systems)
- Paired t-test and adjusted linear regression
- HCQ-SAFE developed in English and Spanish using an iterative process with 30 patient and clinician advisers
Main finding
As reported in the abstract
Change in HCQ adherence (proportion of days covered (PDC)) among HCQ nonadherers, adjusted
Among HCQ nonadherers, adjusted HCQ adherence improved by
47%
95% CI 38–57
Further findings
Implementation: feasibility and time to complete intervention
- Feasibility rating (nurses 21%, pharmacists 29%, physicians 50%), mean
- 8.5
- Time to complete intervention during a visit, minutes (IQR 5-7)
- five
Original publication
A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ ‐ SAFE Study. Arthritis Rheumatol. Published 18 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →